PATENT CLAIM ANALYSIS

Application Number: 15967484
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-09
Patent Classification: ["424", "133100"]

Abstract:
The invention provides methods for treating or preventing microbial (eg, bacterial) infections and means for performing these methods. In particular, treatment of infections requiring rapid and durable therapy is made possible, such as for treating acute conditions such as septicemia, sepsis, SIRS or septic shock. The invention is particularly useful, for example, for treatment of microbes such as for environmental, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. The invention also useful for the treatment of pathogenic bacterial infections in subjects receiving a treatment for a disease or condition, such as a transplant or a treatment for cancer, a viral infection or an autoimmune disease.

Claim (Index 20):
A method for treating a pathogenic bacterial infection in a subject caused by first bacteria that are  E coli, Pseudomonas aeruginosa  or  Klebsiella  bacteria, the method comprising selectively killing first bacteria comprised by the subject by cutting a target site comprised by the genomes of the first bacteria, wherein the cutting is carried out using a Cas nuclease that is programmed by guide RNA to cut the target site, wherein the subject has a cancer, wherein the method comprises administering an immunotherapy to the subject for treating cancer in the subject, wherein the programmed Cas nuclease treats the infection and the immunotherapy is efficacious in the presence of the programmed Cas nuclease to treat the cancer;\n wherein: (a) the immunotherapy comprises administering to the subject an anti-PD-1/PD-L1 axis antibody optionally selected from pembrolizumab, nivolumab, atezolimumab, avelumab and durvalumab; and (b) the cancer is selected from melanoma; renal cell carcinoma; bladder cancer; a solid tumour; non-small cell lung cancer (NSCLC); forehead and neck squamous cell carcinoma (HNSCC); Hodgkin's lymphoma; a cancer that overexpresses PD-L land no mutations in EGFR or in ALK; colorectal cancer and hepatocellular carcinoma.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 91.0
- Lexical Diversity: 1.87179
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15460962', '15160405', '15817135', '15817139', '15817142']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.715568743651408
- 35 USC 102 Novelty (BERT): 0.5126379299914363
- Combined Prediction Score: 0.6952756622854108
- Mean Citation Score: 286.884746
- Max Citation Score: 305.17386
- Similarity Product: 209.0294156755185

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test